Rituximab-associated acute thrombocytopenia: An under-diagnosed phenomenon

American Journal of Hematology

Volumn 84, Issue 4, 2009, Pages 247-250

  Ram, Ron ^a,b   Bonstein, Lilach ^c   Gafter Gvili, Anat ^a,b   Ben Bassat, Isaac ^b   Shpilberg, Ofer ^a,b   Raanani, Pia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLEOMYCIN; COMPLEMENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 1; INTERLEUKIN 6; MITOXANTRONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; ANTINEOPLASTIC AGENT; CYTOKINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

AGED; ARTICLE; ASSAY; BONE MARROW; CASE REPORT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DIARRHEA; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOFLUORESCENCE TEST; LEUKOCYTE COUNT; LEUKOPENIA; MANTLE CELL LYMPHOMA; MONOCLONAL ANTIBODY IMMOBILIZATION OF PLATELET ANTIGEN ASSAY; MYELOID LEUKEMIA; PRIORITY JOURNAL; RASH; RIGOR; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; REVIEW; RISK FACTOR; SECRETION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; CYTOKINES; DRUG ERUPTIONS; FEMALE; FEVER; HUMANS; LEUKOPENIA; LYMPHOMA, MANTLE-CELL; MITOXANTRONE; RISK FACTORS; SPLENOMEGALY; THROMBOCYTOPENIA; VIDARABINE;

EID: 64549108014     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21372     Document Type: Article

References (26)

1. Johnson P, Glennie H. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:3-8. (Pubitemid 36337346)
2. McLaughlin P, Linkm BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a fourdose treatment program. J Clin Oncol 1998;16:2825-2833.
3. Byrd JC, Murphy T, Howard RS. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164. (Pubitemid 32366969)
4. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody. Blood 1999;94:2217-2224.
5. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-1751.
6. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170.
7. Ram R, Raanani P. Rituximab - A double-edged sword: Can one treatment for thrombocytopenia also induce it? Leuk Lymphoma 2008;49:2035-2036.
8. Forstpointner R, Dreyling M, Repp R, et al.German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone [FCM] significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071.
9. Rigamonti C, Volta C, Colombi S, et al. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia 2001;15:186-187.
10. Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 2007;48:2239-2240. (Pubitemid 350091068)
11. Otrock ZK, Mahfouz RA, Oghlakian GO, et al. Rituximab-induced acute thrombocytopenia: A report of two cases. Hematologica 2005;90 Suppl:ECR23.
12. Pamuk GE, Donmez S, Turgut B, et al. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005;78:81.
13. Shah C, Grethlein SJ. Case report of rituximab-induced thrombocytopenia. Am J Hematol 2004;75:263. (Pubitemid 38451111)
14. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-3274.
15. Farina G, Giordano G, Papini S, et al. Rituximab induced thrombocytopenia in marginal lymphoma and hairy cell leukemia: A rare, but possible complication. Report of four cases. Hematologica 2007;92 Suppl. 3:128.
16. Thachil J, Mukherje K, Woodcock B. Rituximab-induced hemorrhagic thrombocytopenia in a patient with hairy cell leukemia. Br J Hematol 2006;135:273-274. (Pubitemid 44401631)
17. Yi JH, Kim SJ, Ahn HK, et al. Rituximab-induced acute thrombocytopenia: A case report and review of the literature. Med Oncol, 2009;26:45-48.
18. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
19. van der Kolk LE, de Haas M, Grillo-López AJ, et al. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002;16:693-699.
20. Gutierrez A, Rodríguez J, Martinez J, et al. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47:111-115.
21. Dinarello CA, Cannon JG. Cytokine measurements in septic shock. Ann Intern Med 1993;119:853-854. (Pubitemid 24012652)
22. Shibazaki M, Kawabata Y, Yokochi T, et al. Complement-dependent accumulation and degradation of platelets in the lung and liver induced by injection of lipopolysaccharides. Infect Immun 1999;67:5186-5191.
23. Michelmann I, Bockmann D, Nürnberger W, et al. Thrombocytopenia and complement activation under recombinant TNF alpha/IFN gamma therapy in man. Ann Hematol 1997;74:179-184.
24. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003;101:2507-2513.
25. Moll S, Orringer EP. Case report: Splenomegaly and splenic sequestration in an adult with sickle cell anemia. Am J Med Sci 1996;312:299-302.
26. Okumura N, Kameko M, Kametani K, et al. Experimental evaluation of serum C3 and C4 assay by laser-nephelometry. II. Normal and physiological variations. Rinsho Byori 1983;31:727-731.